The China biopsy devices market is poised for strong expansion, projected to grow from US$ 612.62 million in 2024 to US$ 1,131.98 million by 2033, reflecting a CAGR of 7.06% between 2025 and 2033, according to the latest analysis by Renub Research. The growing incidence of cancer, increasing demand for minimally invasive diagnostic procedures, continuous technological advancements in biopsy devices, and rising healthcare investments are the primary drivers fueling market growth.
For an in-depth analysis of market trends, forecasts, and competitive dynamics, read the full report here: China Biopsy Devices Market Report.
Growing Cancer Burden Accelerates Biopsy Device Demand
Cancer remains one of the leading causes of mortality in China, with millions of new cases diagnosed annually. Early detection and accurate diagnosis are essential for effective treatment, and biopsy devices play a crucial role in confirming cancer presence and determining its stage.
According to Renub Research, the growing cancer burden, especially lung, breast, liver, and colorectal cancers, has resulted in an increased demand for advanced biopsy techniques such as image-guided and vacuum-assisted biopsies.
Advancements in Biopsy Technologies
Technological innovations are revolutionizing the biopsy devices market in China. Newer robotic-assisted biopsy systems, liquid biopsy technologies, and real-time imaging integration are improving diagnostic accuracy and reducing patient discomfort.
Manufacturers are developing smart biopsy devices with ultrasound or MRI guidance, disposable components, and enhanced safety features. These advancements are boosting adoption rates in hospitals and diagnostic centers across the country.
Minimally Invasive Procedures Gain Popularity
Minimally invasive biopsy techniques such as needle-based, stereotactic, and vacuum-assisted biopsies are increasingly preferred over traditional surgical biopsies due to their lower risk, shorter recovery times, and reduced hospital costs.
Ultrasound-guided core needle biopsies and liquid biopsies, which analyze circulating tumor DNA (ctDNA) from blood samples, are gaining momentum as effective diagnostic tools in China’s oncology care.
Rising Healthcare Investments in China
The Chinese government is heavily investing in healthcare infrastructure and diagnostic technologies to improve cancer detection rates. Nationwide screening programs, government-funded cancer hospitals, and the adoption of state-of-the-art diagnostic equipment are driving biopsy device demand.
The market is also benefiting from public-private partnerships and international collaborations with global medical device companies for technology transfer and R&D.
Market Segmentation
By Product Type
- Needle-Based Biopsy Instruments (Core Needle Biopsy, Fine Needle Aspiration, Vacuum-Assisted Biopsy)
- Biopsy Guidance Systems (Ultrasound, MRI, CT)
- Biopsy Guns
- Biopsy Forceps
- Other Consumables (Trays, Needles, Reagents)
By Application
- Breast Biopsy
- Lung Biopsy
- Liver Biopsy
- Kidney Biopsy
- Other Organ Biopsies
By End User
- Hospitals
- Diagnostic Imaging Centers
- Cancer Research Institutes
- Specialty Clinics
Key Growth Drivers
1. Rising Cancer Incidence
China records millions of new cancer cases each year, creating a huge demand for precise diagnostic devices, particularly for breast, lung, and liver cancers.
2. Technological Innovations
The integration of AI-powered imaging, robotic-assisted biopsies, and real-time pathology analysis are transforming cancer diagnosis in China.
3. Growing Preference for Outpatient Procedures
The trend toward day-care centers and outpatient diagnostic services is driving the use of compact, portable biopsy devices.
4. Expanding Healthcare Infrastructure
Government investments in rural healthcare facilities, cancer screening programs, and advanced hospitals are expanding access to biopsy procedures.
Challenges in the China Biopsy Devices Market
- High costs of advanced biopsy devices, particularly robotic-assisted and image-guided systems.
- Shortage of skilled medical professionals trained in minimally invasive techniques.
- Limited awareness about early cancer detection in rural and remote areas.
- Regulatory challenges in approving new medical device technologies.
Opportunities and Future Trends
- Liquid Biopsy Growth: Liquid biopsies are emerging as a non-invasive alternative, allowing early cancer detection through blood samples.
- Domestic Manufacturing: Chinese companies are increasingly investing in local production of biopsy devices to reduce dependence on imports.
- AI and Data Analytics: The integration of artificial intelligence in diagnostic imaging and biopsy interpretation is expected to enhance accuracy.
- Precision Medicine: The shift towards personalized oncology treatment will require advanced and precise biopsy devices.
Competitive Landscape
The China biopsy devices market is dominated by both global medical technology leaders and domestic manufacturers. Key players include:
- Becton, Dickinson and Company (BD)
- Hologic Inc.
- Medtronic Plc
- Cook Medical LLC
- Argon Medical Devices
- C.R. Bard (Bard Biopsy Systems)
- Devicor Medical Products Inc.
- Biocept Inc. (Liquid Biopsy)
- Chinese Companies: Mindray Medical, Lepu Medical, and others.
These companies are focusing on R&D collaborations, mergers, and strategic partnerships to expand their presence in China.
Regional Insights
The market growth varies across Chinese regions:
- Eastern China (Shanghai, Jiangsu, Zhejiang): Leads in biopsy device adoption due to advanced healthcare facilities.
- Northern China (Beijing, Tianjin): High demand driven by large cancer treatment centers.
- Southern China (Guangdong, Fujian): Rising private hospital and diagnostic chain expansions.
- Western China: Slower adoption but growing due to government-funded healthcare programs.
Future Market Outlook
By 2033, the China biopsy devices market will continue to expand, fueled by technological breakthroughs, increasing cancer screening initiatives, and rising awareness of early detection. Adoption of robotic-assisted and AI-powered biopsy technologies will drive the next phase of growth.
FAQs on China Biopsy Devices Market
1. What is the size of the China biopsy devices market in 2024?
The market is valued at US$ 612.62 million in 2024.
2. What is the projected size by 2033?
The market is expected to reach US$ 1,131.98 million by 2033.
3. What is the growth rate of the market?
The market will grow at a CAGR of 7.06% from 2025–2033.
4. What factors are driving market growth?
Rising cancer prevalence, demand for minimally invasive diagnostics, and biopsy technology advancements.
5. Which biopsy techniques are gaining popularity?
Core needle biopsies, vacuum-assisted, and liquid biopsies are seeing rapid adoption.
6. Who are the leading players in the market?
Major companies include BD, Hologic, Cook Medical, and Medtronic.
7. What role does the government play in this market?
The Chinese government is investing in screening programs and advanced healthcare infrastructure.
8. Are domestic manufacturers emerging in this market?
Yes, companies like Mindray Medical and Lepu Medical are gaining market share.
9. What challenges does the market face?
High device costs, regulatory complexities, and skill shortages are key challenges.
10. What trends will dominate the future?
AI integration, liquid biopsy, and precision medicine will shape the future of cancer diagnostics.
New Publish Report:
- China Ready Drink Tea and Coffee Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- China Protein Ingredients Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
- China Processed Meat Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033
About the Company – Renub Research
Renub Research is a Market Research and Consulting Company with more than 15 years of experience, especially in international Business-to-Business Research, Surveys, and Consulting. We provide a wide range of business research solutions that help companies make better business decisions.
We partner with clients across all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele includes key players in Healthcare, Travel & Tourism, Food & Beverages, Power & Energy, Information Technology, Telecom & Internet, Chemicals, Logistics & Automotive, Consumer Goods & Retail, Building & Construction, and Agriculture.
Our core team comprises experienced professionals with graduate, postgraduate, and Ph.D. qualifications in Finance, Marketing, Human Resources, Bio-Technology, Medicine, Information Technology, Environmental Science, and more.
Media Contact
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +91-120-421-9822 (IND) | +1-478-202-3244 (USA)
Email: rajat@renub.com
